Gilbert H. Kliman, a director at GLAUKOS Corp (), recently reported transactions involving the company’s common stock. On August 19, 2026, Mr. Kliman sold 2,500 shares of common stock at a price of $190.0 per share, totaling $475,000. The sale came as GLAUKOS stock trades near its 52-week high of $191.62, following a remarkable 106% return over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels, with 14 additional ProTips available to subscribers.
On the same day, Mr. Kliman also acquired 2,500 shares of common stock at a price of $25.77 per share, amounting to $64,425. This acquisition was a result of exercising stock options, which had an exercise price of $25.77 and were exercisable since May 31, 2018, with an expiration date of December 13, 2027.
Following these transactions, Mr. Kliman’s direct beneficial ownership of GLAUKOS common stock stands at 37,406 shares. This figure includes 2,501 restricted stock units that have not yet vested or been delivered, as well as restricted stock units that have vested but whose delivery has been deferred by Mr. Kliman. Additionally, Mr. Kliman holds 12,500 stock options.
In other recent news, Glaukos Corporation reported second-quarter 2026 financial results that surpassed Wall Street expectations. The company achieved a total revenue of $185.6 million, marking a 49.5% year-over-year growth, and exceeded analyst projections of $151.5 million. Following these results, Glaukos raised its full-year sales outlook, demonstrating strong performance driven by its iDose and Epioxa products. Analysts responded positively, with H.C. Wainwright raising its price target to $195, Stifel to $190, Needham to $201, and Truist Securities to $215, all maintaining a Buy rating. Stifel highlighted positive surveys on iDose and Epioxa, suggesting a realistic revenue target of $1.0 billion or more by 2027. Truist Securities’ valuation included a significant contribution from iDose, reflecting its anticipated future performance. These developments underscore a robust outlook for Glaukos, as reflected in the increased price targets from multiple firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.